The opioid epidemic continues to claim tens of thousands of lives each year, despite ongoing public health efforts to curb overdoses and expand access to care. While a wide variety of treatment approaches are used across the country, a growing body of evidence underscores one truth: medication-assisted treatment (MAT) with buprenorphine or methadone is the gold standard for opioid use disorder (OUD) care.
A recent study published in JAMA Network Open adds to that evidence, showing that individuals treated with buprenorphine or methadone as part of their MAT regimen were significantly less likely to overdose or suffer other opioid-related health emergencies compared to those receiving other forms of treatment—or no treatment at all.
These findings are particularly important at a time when both policymakers and insurers are determining how best to structure access to OUD treatment in the face of an ongoing crisis.
The Study at a Glance
The study evaluated the health outcomes of nearly 41,000 individuals, age 16 and older, across diverse races and ethnicities. Researchers used data collected by Optum Labs, a subsidiary of UnitedHealth Group, covering the period between October 2014 and December 2017.
Participants in the study were covered either by commercial insurance or Medicare Advantage plans. This allowed researchers to track treatment and health outcomes in real-world settings where coverage type, access barriers, and patient demographics can greatly influence recovery trajectories.
The researchers compared MAT with buprenorphine and methadone against five other treatment approaches:
- Inpatient detoxification or residential services
- Intensive outpatient or partial hospitalization services
- Outpatient counseling
- MAT with naltrexone (an opioid relapse prevention medication)
- No treatment
They then analyzed health outcomes at three and twelve months following the initiation of treatment.
Key Findings: Buprenorphine and Methadone Save Lives
The results were striking. Patients receiving MAT with buprenorphine or methadone were significantly more protected against overdose and other opioid-related emergencies compared to those who received other treatments.
- Overdose Risk Reduction:
- Patients were 76% less likely to overdose within three months of beginning buprenorphine or methadone treatment.
- They were 59% less likely to overdose after twelve months.
- Reduced Serious Health Events:
- Within three months, patients on buprenorphine or methadone were 32% less likely to experience opioid-related health crises requiring immediate care.
- After twelve months, the likelihood decreased by 26%.
By contrast, other treatment methods—including detoxification, residential services, and naltrexone—showed no significant reduction in overdose or serious health risks after several months.
Why Buprenorphine and Methadone Work
Buprenorphine and methadone are both medications for opioid use disorder (MOUD) that function by stabilizing brain chemistry disrupted by chronic opioid use.
- Methadone is a full opioid agonist that eliminates withdrawal symptoms and cravings without producing the intense “high” associated with illicit opioid use. It allows patients to function normally while reducing the risk of relapse.
- Buprenorphine, a partial opioid agonist, has a “ceiling effect” that lowers the risk of misuse while still easing cravings and withdrawal. Often prescribed in combination with naloxone (as Suboxone), it can be administered in outpatient settings, making it more accessible.
Both medications support long-term recovery by reducing the cycle of withdrawal and relapse that fuels overdose risk. Importantly, MAT with these medications is not simply “substituting one drug for another,” as critics sometimes argue. Instead, it is a scientifically validated treatment that restores stability, reduces overdose deaths, and improves quality of life.
The Role of Insurance Coverage
One of the most significant implications of this study is its potential impact on insurance coverage for MAT. Despite the overwhelming evidence supporting buprenorphine and methadone, barriers remain. Many insurance plans still impose restrictions on access, such as prior authorization requirements, dosage limits, or time caps on treatment.
The study’s authors argue that insurers should reevaluate these restrictions in light of the clear benefits of MAT. In their conclusion, they noted:
“Opportunities exist for health plans to reduce restrictions on use for MOUD and the need for treatment models that prioritize access to and retention of MOUD treatment.”
This recommendation could help shift the treatment landscape by encouraging more consistent coverage for buprenorphine and methadone. For patients, that means greater access to life-saving care without unnecessary administrative hurdles.
Misconceptions About MAT
Despite its effectiveness, MAT continues to face stigma from both the public and some treatment providers. Critics sometimes view the use of methadone or buprenorphine as replacing one addiction with another. However, decades of research contradict this perspective, showing that patients who remain on MAT:
- Experience significantly lower relapse rates
- Have reduced risk of fatal overdose
- Are more likely to stay in treatment
- See improvements in social and occupational functioning
The persistence of stigma often discourages patients from pursuing MAT or leads providers to recommend less effective alternatives such as short-term detoxification, which carries a high risk of relapse and overdose.
What the Findings Mean for Providers
For treatment providers, the study reinforces the importance of offering MAT with buprenorphine or methadone as a frontline option for OUD. While counseling, peer support, and behavioral therapies remain vital components of comprehensive care, MAT should be recognized as the foundation of effective OUD treatment.
Providers who resist MAT may inadvertently increase patient risk, especially during the vulnerable months immediately following detoxification or treatment initiation. Integrating MAT into existing programs—and advocating for insurance coverage to support it—can help save lives and improve long-term outcomes.
Implications for Public Health Policy
At the policy level, the study adds to mounting evidence that expanding MAT access is essential to addressing the opioid epidemic. Policymakers may consider measures such as:
- Removing caps on the number of patients a provider can treat with buprenorphine
- Increasing funding for methadone clinics in underserved areas
- Supporting telehealth-based MAT to reach rural and remote populations
- Mandating parity in insurance coverage for MAT compared to other forms of treatment
Each of these steps could help reduce the treatment gap, which remains significant. Estimates suggest that fewer than one in three people with OUD currently receive any form of medication treatment.
Conclusion
The findings from the JAMA Network Open study are clear: MAT with buprenorphine or methadone is superior to other forms of treatment in preventing overdoses and serious opioid-related health events. Patients who receive these medications are significantly less likely to suffer an overdose months after beginning care, compared to those who undergo detox, counseling, or naltrexone treatment alone.
As the opioid epidemic continues to devastate communities, the evidence is stronger than ever that methadone and buprenorphine must be at the center of the nation’s response. Overcoming stigma, ensuring insurance coverage, and expanding access are all critical steps in ensuring that individuals with OUD receive the best chance at recovery—and survival.
The message for patients, providers, insurers, and policymakers is the same: when it comes to saving lives from opioid overdoses, buprenorphine and methadone are not just effective—they are essential.
